Harmony Biosciences Holdings (HRMY)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $1.94B
Last updated: Nov 17, 2026 at 4:15 PM ET
Harmony Biosciences Holdings (HRMY) Stock Chart
Harmony Biosciences Holdings (HRMY) has a latest price of $32.96 on Nov 17, 2026, 24.2% below its 52-week high of $43.49. Its price fell 3.9% over the past 12 months. The month-end price fell 6.5% over the 5 years through Oct 2026, a compound annual decline of 1.3%.
Price Chart
From Aug 2020 to Oct 2026, its highest month-end close was $59.77 in Nov 2022 and its lowest $23.54 in Oct 2023, adjusted for splits.
Month-end closes, adjusted for splits. Dividends are not included.
Chart HRMY with Advanced Charting
Daily candlesticks, valuation multiples, side-by-side comparisons and drawings for HRMY.
Free with a GNG account. No credit card.
Price Performance
Over the past 3 months the price fell 15.1%, and over 6 months it rose 10.5%. The month-end price rose 64.7% over the 3 years through Oct 2026, a compound annual rate of 18.1%.
| Period | Change |
|---|---|
| 1 month | -13.1% |
| 3 months | -15.1% |
| 6 months | +10.5% |
| 12 months | -3.9% |
| 12 months, with dividends | -3.9% |
| Period | Change | Per year |
|---|---|---|
| 3 years | +64.7% | +18.1% |
| 5 years | -6.5% | -1.3% |
Price by Year
Its best calendar year was 2022, when the price rose 29.2%, and its weakest was 2023, when it fell 41.4%.
| Year | Close | Change |
|---|---|---|
| 2026 through Oct 2026 | $38.76 | +3.6% |
| 2025 | $37.42 | +8.7% |
| 2024 | $34.41 | +6.5% |
| 2023 | $32.30 | -41.4% |
| 2022 | $55.10 | +29.2% |
| 2021 | $42.64 | +18.0% |
Trading Range
The price is 14.3% below its 50-day average of $38.46 and 4.6% below its 200-day average of $34.55.
| Measure | Value | Price vs |
|---|---|---|
| Latest price (Nov 17, 2026) | $32.96 | |
| 52-week high | $43.49 | -24.2% |
| 52-week low | $25.90 | +27.3% |
| 50-day average | $38.46 | -14.3% |
| 200-day average | $34.55 | -4.6% |
Price Risk
Over 3 years, its largest fall from a peak was 37.6%.
| Measure | Value |
|---|---|
| 1-year beta | 0.64 |
| Largest fall, 1 year | -34.5% |
| Largest fall, 3 years | -37.6% |
Valuation
Harmony Biosciences Holdings traded at 11.2x earnings at the end of 2025, against a 5-year median of 10.9x.
Advanced Charting Features
Advanced Charting is free with a GNG account, and signed-in members get it in place of the price chart above.
- Valuation multiples. Daily P/E, price to sales, cash flow and book value, PEG and PEGY, drawn behind the price wherever the company's data supports them.
- Price charts and drawings. Candlestick, OHLC, line and area charts with volume and earnings, dividend and split markers, plus trend lines, levels and notes kept in your account.
- Side-by-side compare. Two stocks next to each other on one metric and time span, each chart with its own price scale.
- Projections and saved views. Pick a start and an end point to see the price return, dividends and total return between them, and save views to open later.
Frequently Asked Questions About HRMY
What is HRMY's 1-year price change?
Harmony Biosciences Holdings's price fell 3.9% over the past 12 months. With dividends included, the 12-month total return was -3.9%.
What is HRMY's 5-year price change?
Harmony Biosciences Holdings's month-end price fell 6.5% over the 5 years through Oct 2026, a compound annual decline of 1.3%. These figures leave out dividends.
What is HRMY's 52-week high and low?
Harmony Biosciences Holdings's 52-week high is $43.49 and its 52-week low is $25.90. Its latest price of $32.96 on Nov 17, 2026 is 24.2% below the high.
What is HRMY's beta?
Harmony Biosciences Holdings's 1-year beta against the S&P 500 is 0.64, so its price has moved less than the market over the past year. Its largest fall from a peak over the past year was 34.5%.
Is the HRMY chart free?
Yes. Advanced Charting for HRMY is free with a GNG account, and no credit card is needed. It adds daily candlestick and line charts with volume, valuation multiples, side-by-side comparisons, drawings and saved views.
HRMY pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors, Government Contracts